EUVIMEDEUVIMED entdecken
Open Access

High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin

Louise Dahl Hultqvist iD, Jens Bo Andersen, Carl Martin Nilsson, Charlotte Uldahl Jansen, Morten Rybtke, Tim Holm Jakobsen iD, Thomas Eiland Nielsen, Klaus Qvortrup, Claus Moser, Michael Graz, Katrine Qvortrup, Tim Tolker-Nielsen iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01481-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Louise Dahl Hultqvist und 12 weiteren Autor:innen. Beteiligte Einrichtung: Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, De…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Urinary Tract Infections, Biofilms, Anti-Bacterial Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sygeforsikringen Danmark, Novo Nordisk Fonden (NNF), The Danish Innovation Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent urinary tract infections (UTIs) in hospitalized patients constitute an important medical problem. It is estimated that 75% of nosocomial UTIs are associated with urinary tract catheters with P. aeruginosa being a species that forms biofilms on these catheters. These infections are highly resistant to standard-of-care antibiotics, and the effects of the host immune defenses, which allows for development of persistent infections. With antibiotics losing their efficacy, new treatment options against resilient infections, such as catheter-associated urinary tract infections (CAUTIs), are critically needed. Central to our anti-biofilm approach is the manipulation of the c-di-GMP signaling pathway in P. aeruginosa to switch bacteria from the protective biofilm to the unprotected planktonic mode of life. We recently identified a compound (H6-335-P1), that stimulates the c-di-GMP degrading activity of the P. aeruginosa BifA protein which plummets the intracellular c-di-GMP content and induces dispersal of P. aeruginosa biofilm bacteria into the planktonic state. In the present study, we formulated H6-335-P1 as a hydrochloride salt (Disperazol), which is water-soluble and facilitates delivery via injection or oral administration. Disperazol can work as a monotherapy, but we observed a 100-fold improvement in efficacy when treating murine P. aeruginosa CAUTIs with a Disperazol/ciprofloxacin combination. Biologically active Disperazol reached the bladder 30 min after oral administration. Our study provides proof of concept that Disperazol can be used in combination with a relevant antibiotic for effective treatment of CAUTIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaUrinary Tract InfectionsBiofilmsAnti-Bacterial AgentsCiprofloxacinPseudomonas InfectionsCyclic GMPAnimalsMiceCatheter-Related InfectionsFemaleMicrobial Sensitivity Tests

Stichwörter der Autor:innen

CAUTIPseudomonas aeruginosaanti-biofilm compoundantibiotic resistance (AMR)biofilmc-di-GMP regulationinfection

Substanzen

Anti-Bacterial AgentsCiprofloxacinbis(3',5')-cyclic diguanylic acidCyclic GMP

Autor:innen und Institutionen

  • Costerton Biofilm Center, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Chemistry, Technical University of Denmark, Lyngby, Denmark.
  • Department of Biomedical Sciences, CFIM, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Louise Dahl Hultqvist, Tim Holm Jakobsen, Tim Tolker-Nielsen, Michael Givskov

Förderung

  • Sygeforsikringen Danmark
  • Novo Nordisk Fonden (NNF)
  • The Danish Innovation Foundation

Zitieren

APA

Hultqvist, L. D., Andersen, J. B., Nilsson, C. M., Jansen, C. U., Rybtke, M., Jakobsen, T. H., Nielsen, T. E., Qvortrup, K., Moser, C., Graz, M., Qvortrup, K., Tolker-Nielsen, T., & Givskov, M. (2024). High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01481-23

Vancouver

Hultqvist LD, Andersen JB, Nilsson CM, Jansen CU, Rybtke M, Jakobsen TH, et al. High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01481-23

BibTeX
@article{Hultqvist2024,
  author = {Hultqvist, Louise Dahl and Andersen, Jens Bo and Nilsson, Carl Martin and Jansen, Charlotte Uldahl and Rybtke, Morten and Jakobsen, Tim Holm and Nielsen, Thomas Eiland and Qvortrup, Klaus and Moser, Claus and Graz, Michael and Qvortrup, Katrine and Tolker-Nielsen, Tim and Givskov, Michael},
  title = {High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01481-23}
}
Kostenlos starten →